XT
ALGS icon

XTX Topco’s Aligos Therapeutics ALGS Stock Holding History

XTX Topco’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,196
Closed -$105K – 4115
2026
Q1 		$105K Sell
14,196
-8,857
-38% -$67.2K ﹤0.01% 3086
2025
Q4 		$215K Buy
+23,053
New +$217K 0.01% 2346
2025
Q3 		– Sell
-13,849
Closed -$99.9K – 2514
2025
Q2 		$99.9K Buy
+13,849
New +$82.9K ﹤0.01% 1886
2024
Q3 		– Sell
-1,426
Closed -$12.5K – 2043
2024
Q2 		$12.5K Sell
1,426
-369
-21% -$6.49K ﹤0.01% 1670
2024
Q1 		$44K Buy
1,795
+765
+74% +$15.2K 0.01% 1488
2023
Q4 		$17.1K Buy
+1,030
New +$17.7K ﹤0.01% 1380
2022
Q2 		– Sell
-1,757
Closed -$94K – 825
2022
Q1 		$94K Buy
+1,757
New +$141K 0.04% 525

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

XTX Topco's ALGS Position: Q2 2026 in Review

XTX Topco sold out of Aligos Therapeutics (ALGS) in Q2 2026, closing a stake of 14,196 shares — an estimated $105K sold.

XTX Topco first reported a position in ALGS in Q1 2022 and held it in 7 quarters. The position peaked at $215K in Q4 2025. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

  • XTX Topco reported no remaining Aligos Therapeutics position as of Q2 2026 after selling out during the quarter.
  • XTX Topco sold 14,196 Aligos Therapeutics shares in Q2 2026, an estimated $105K.
  • XTX Topco first reported a position in Aligos Therapeutics in Q1 2022 and held it in 7 quarters.
  • XTX Topco's Aligos Therapeutics position peaked at $215K in Q4 2025.
  • 31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.